Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome (PINCom)
2024-519832-17-00Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in complex regional pain syndrome (CRPS), sponsored by Rigshospitalet. Primary endpoint: Overall feasibility of a full-scale trial. Started Oct 2025; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on 2024-519832-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519832-17-00.